Uterine Adenosarcoma in Obese/Overweight Patients; A Report of Two Cases

Shota Asano¹, Takashi Shibata¹, Tomoki Kodera¹, Yoshihiro Ikura²* and Tetsuya Oishi¹

¹Department of Obstetrics and Gynecology, Takatsuki General Hospital, Takatsuki 569-1192, Japan
²Department of Pathology, Takatsuki General Hospital, Takatsuki 569-1192, Japan

Abstract

Uterine adenosarcomas are an uncommon gynecological neoplasm consisting of benign epithelial and malignant mesenchymal components and usually presenting as a polypoid mass. We report herein two cases of uterine adenosarcoma. Both of the patients were obese/overweight (body mass index 32 kg/m² and 27 kg/m², respectively), and controlling obesity and metabolic disorders seemed to be the key to prevent their post-operative tumor recurrence.

Keywords: Adenosarcoma; Uterus; Oncogenesis; Obesity; Estrogen

Introduction

Uterine adenosarcomas are a rare gynecological neoplasm consisting of combination of benign glandular epitheliums and malignant mesenchymal cells [1]. From the initial report of Clement and Scully in 1974, several comprehensive pathologic studies have revealed their pathobiological characteristics in detail; the tumors usually present as a polypoid mass and are frequently misdiagnosed as benign conditions [2-3-7]. However, pathological mechanism of oncogenesis of uterine adenosarcoma is still obscure.

In uterine body malignancies, excess estrogen exposure and obesity are considered potential pathogenic factors. Obese women have an increased risk (approximately 2-3 folds compared with non-obese women) of uterine cancer, which is explained mainly by increase in adipocyte-derived estrogens and insulin resistance [8-10]. In addition, mortality of obese/overweight patients with uterine cancer was about two-fold greater than that of normal body-weight patients (19.1 vs 10.68 per 100,000 patients) [11].

We report herein two obese/overweight patients with uterine adenosarcoma. These cases suggested possible contribution of metabolic disorders to the oncogenic processes.

Case reports

Case 1

A 72-year-old obese (body mass index 32 kg/m²) nulligravida consulted to our hospital because of genital bleeding and lower abdominal pain. She suffered from type 2 diabetes (HbA1c 7.2%), dyslipidemia, fatty liver and hypertension, and had been treated as an outpatient of the clinic (Figure 1).

Pathologic diagnosis was difficult and needed several months. The tumor was diagnosed at last as being uterine adenosarcoma, on the basis of characteristic phyllodes-like appearance and repeated recurrences (Figure 3).

Figure 1: An abdominal computed tomography of Case 1. The liver shows mottled fatty change.

Figure 2: A removed vaginal polypoid lesion of Case 1.

Figure 3: Histological section of Case 1. Note the phyllodes-like appearance of the tumor.
Uterine Adenosarcoma in Obese/Overweight Patients; A Report of Two Cases

A total hysterectomy and bilateral salpingo-oophorectomy was performed. Pelvic lymph node dissection was disturbed by pelvic space narrowing related to obesity. A recurrent tumor was found in the specimen, to be present within inner 1/2 layer of myometrium. The final diagnosis was uterine adenosarcoma, FIGO stage Ib (T1b, Nx, M0). She received a strict diet and blood glucose/lipid control, and her body weight has been decreasing. At present (two years after hysterectomy), there is no evidence of recurrence.

Case 2

A 46-year-old woman (gravid 4, para 2) presented with abnormal genital bleeding and vaginal discomfort. She was overweight (body mass index 27 kg/m2), but had neither diabetes nor dyslipidemia. A gynecologist found a chicken-egg-sized polypoid mass in her vagina, and excised the lesion. Pathological examination revealed that the polypoid lesion had benign columnar epitheliums but contained atypical and excised the lesion. Pathological examination revealed that the lesion in Case 2. (Hematoxylin-eosin stain, original magnification x100)

The lesion was diagnosed as being uterine adenosarcoma and a total hysterectomy and bilateral salpingo-oophorectomy, and pelvic lymph node dissection was performed. A residual tumor was present within inner 1/2 layer of myometrium. The final diagnosis was uterine adenosarcoma, FIGO stage Ib (T1b, N0, M0). Post-operative course was uneventful, and tumor recurrence has not yet been reported.

Discussion

It is generally considered that various human malignancies, including gynecological cancers, have close associations with lifestyle-related metabolic disorders, i.e., hyperglycemia, dyslipidemia, hypertension and obesity [12,13]. These metabolic disorders have been suggested to play pathogenic roles in oncogenic processes of the malignant tumors [14]. Endometrial cancer is a representative metabolic disorder-related malignancy, in which excess estrogen production from peripheral adipocytes increasing due to obesity is thought to stimulate endometrial proliferation and oncogenesis [9]. Some investigators insisted on potential contribution of additional mediators (e.g. leptin, insulin resistance, etc.) that link obesity to endometrial cancer [15-17].

Certainly, such the common pro-carcinogenic factors related to metabolic disorders may also impact on development of uterine cancers. However, it was confirmed even in their own studies that the obesity-estrogen axis was a primary pathway of endometrial carcinogenesis in obese patients [15,16]. Obesity and excess estrogen are also recognized to be risks of developing uterine sarcomas [16]. Concerning uterine adenosarcoma, although no obvious association with obesity has been described in an established textbook [1], an American cohort study of uterine adenosarcoma showed a high median body-weight (82 kg), suggesting that obesity/overweight potentially increases its risk [19]. As seen in our Case 1, whose pelvic lymph node dissection was impossible due to obesity, obesity potentially disturbs appropriate treatments for uterine malignancies and consequently worsens patients’ prognoses [11]. Management of obesity is considered to be important not only in prevention of uterine adenosarcoma but also in optimization of therapies for it. Also direct suppression of estrogen production may be effective against uterine adenosarcoma. Usefulness of aromatase inhibitors for endometrial stromal sarcoma has already been recognized [20,21]. A recent research suggested that in uterine adenosarcoma the sarcoma element but not the glandular element was neoplasia [22]. Accordingly, uterine adenosarcoma can be considered a subtype of endometrial stromal sarcoma, and administration of aromatase inhibitors is expected, not only for endometrial stromal sarcoma but also for uterine adenosarcoma, in both, therapy and prevention [23].

Both of our two patients are obese/overweight individuals and seem to have good application of these treatments as tumor recurrence preventions. Obese patients, especially the elders like Case 1, frequently have other lifestyle-related metabolic disorders. In such cases, aggressive interventions against hyperglycemia and dyslipidemia may suppress general oncogenic processes via insulin-resistance and oxidative stress [14]. In fact, in Case 1 the strict diet and blood glucose/lipid control, which could induce the weight reduction, may have been contributing to prevention of tumor recurrence. Taken together, it should be emphasized that controlling obesity and metabolic disorders is important in prevention of uterine adenosarcoma development and in suppression of its post-operative recurrence. In addition, aromatase inhibitors may become a superior adjuvant therapy for uterine adenosarcomas.

In conclusion, uterine adenosarcomas are rare gynecological malignancies and their oncogenic mechanisms are still obscure. Obesity and excess estrogens are thought to be important risks of uterine adenso sarcoma as well as the other uterine body malignances. Controlling of obesity and interventions to background metabolic disorders are potential therapeutic options for uterine adenosarcomas.

Acknowledgements

The authors would like to thank Ms Kitaguchi for her excellent assistance in preparation of manuscript.
Uterine Adenosarcoma in Obese/Overweight Patients: A Report of Two Cases

References


